XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
公司代码XOMA
公司名称XOMA Royalty Corp
上市日期Jun 06, 1986
CEOMr. Owen P. Hughes, Jr.
员工数量13
证券类型Ordinary Share
年结日Jun 06
公司地址2200 Powell Street
城市EMERYVILLE
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编94608
电话15102047200
网址https://xoma.com/
公司代码XOMA
上市日期Jun 06, 1986
CEOMr. Owen P. Hughes, Jr.